June 12, 2014 News by Charles Moore Researchers Report Alternate Explanation Discovery Of How And Why CCSVI Treatment Works In MS Patients A new study may offer new insight on beneficial effects of “chronic cerebrospinal venous insufficiency” (CCSVI or CCVI) treatment for Multiple Sclerosis (MS) and certain other disease conditions. CCSVI is the controversial theory that blocked neck veins are a major factor in many MS cases proposed by Italian physician…
June 11, 2014 News by Charles Moore Better MS Tracking Tool Developed by Robarts Institute Scientists At University of Western Ontario A team of magnetic imaging scientists led by Dr. Ravi Menon, PhD, at the University of Western Ontario’s Robarts Research Institute have developed a better way to track the progression of Multiple Sclerosis (MS) from its very early stages. The Robarts researchers used a technique called Quantitative Susceptibility…
June 10, 2014 News by admin Experimental Relapsing Multiple Sclerosis Therapy From Receptos Reveals Positive Endpoint Data in Phase 2 Results Following the promising results of prior trials, Receptos, Inc., a biopharmaceutical company engaged in the treatment of immune and metabolic diseases, announced that the Phase 2 portion of the RADIANCE trial has met the primary endpoint, a reduction in MRI brain lesion activity in patients with relapsing multiple sclerosis…
June 9, 2014 News by Maureen Newman ImStem Uses Embryonic Stem Cells to Treat Animal Model of Multiple Sclerosis ImStem Biotechnology, Inc. is one step closer to harnessing the power of human embryonic stem cells (hESCs) to treat multiple sclerosis. Most recently, ImStem announced the successful treatment of an animal model of multiple sclerosis (experimental autoimmune encephalitis, EAE) using mesenchymal stem cells derived from hESCs (hES-MSCs). Using hES-MSCs…
June 9, 2014 News by Maureen Newman Chronic Cerebrospinal Venous Insufficiency Is Not a Cause of Multiple Sclerosis Charles Moore, Science and Research Editor of Multiple Sclerosis News Today, recently reported two controversial, potential treatment options for multiple sclerosis. The first, “liberation therapy,” was conjured by Dr. Paolo Zamboni in…
June 6, 2014 by Patricia Silva, PhD Researchers Present Guide To Compassion Fatigue Fighting Through Self Care At MS Conference The first step to effective caregiving for those with Multiple Sclerosis is caring for oneself, according to researchers Marie Namey, a clinical nurse specialist in Multiple Sclerosis at the Cleveland Clinic Main Campus, and Ellen Reardon, a dietitian at Walden Behavioral Care. The presentation āCompassion Fatigue: Caring for the…
June 5, 2014 News by Patricia Silva, PhD International Committee Recommends Revision of MS Definitions snig / Shutterstock.com Following yesterday’s publication ofĀ āMultiple Sclerosis Management ā A Changing Landscape 2013,ā a report outlining ongoing goals and focus points for advancing MS drugs and treatments, as a result of a meeting of specialists in Vienna, Austria, a new article…
June 5, 2014 News by Maureen Newman Biogen Idec Investigates Tysabri in Secondary-Progressive Multiple Sclerosis Patients Biogen Idec is currently sponsoring a clinical trial evaluating its therapy Tysabri (natalizumab) in patients with secondary-progressive multiple sclerosis. Although relapse-remitting multiple sclerosis is more common and well-researched, the National Multiple Sclerosis Society estimates approximately half of relapse-remitting patients will transition to secondary-progressive within 19 years of diagnosis. The…
June 4, 2014 News by Patricia Silva, PhD New Report Outlines Scholars’ Meeting Concerns Over MS Treatment, Drug Development A new report was recently released outlining researchers’ ongoing goals and focus points for advancing MS drug development and treatment options. āMultiple Sclerosis Management ā A Changing Landscape 2013ā is the result of a meeting held in Vienna, Austria in April of 2013Ā that brought together 372…
June 4, 2014 News by admin New Analysis Suggests Some MS Patients Need Extra Encouragement For Physical Activity A secondary analysis of data from a previous trial of an Internet-based exercise intervention in patients with Multiple Sclerosis (MS) suggests that the program wasnāt as effective on the subgroups of MS patients to whom physical activity is more important, reports John Gever…
June 3, 2014 News by Maureen Newman Interferon Beta-1a Protects Relapse-Remitting MS Patients from Brain Volume Reduction Research from the State University of New York at Buffalo suggests a protective link between interferon beta-1a treatment and brain volume loss (atrophy) in patients with relapse-remitting multiple sclerosis. Michael Dwyer, PhD, presented his study at the 2014 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and…
June 3, 2014 News by Charles Moore Another Canadian Study Finds No Link Between Blocked Neck Veins And MS Another study, in what has become a succession of Canadian studies, has failed to detect a link between blocked neck veins and multiple sclerosis proposed by Italian physician and researcher Dr. Paolo Zamboni in 2008 (a report in the Lancet noted that this hypothesis was originally posed by…
June 2, 2014 News by Charles Moore Genzyme Resubmits Multiple Sclerosis Drug Lemtrada For FDA sBLA Approval Review Cambridge, Mass. Based Genzyme, a Sanofi subsidiary, announced May 30 that the U.S. Food and Drug Administration (FDA) has accepted for review the companyās resubmission of its supplemental Biologics License Application (sBLA) seeking approval of its proprietary drug Lemtrada (alemtuzumab) for treatment of relapsing forms of multiple sclerosis (MS).
June 2, 2014 News by Patricia Silva, PhD UT Medicine Multiple Sclerosis Clinic Selected As MS Partner In Care The network of nationally recognized Multiple Sclerosis centers continues to grow throughout the United States. Recently, theĀ Multiple Sclerosis Clinic at University of Texas (UT) Medicine San Antonio was selected as the new Multiple Sclerosis Partner in Care, a recognition granted byĀ the National Multiple Sclerosis Society. The new…
May 30, 2014 News by Charles Moore Is Vitamin D Supplementation Effective For Fighting Multiple Sclerosis, Fibromyalgia, and Parkinson’s? Sturgeon Bay, Wisconsin chiropractor, naturopath and health blogger Dr. J.G. Moellendorf, DC, ND, LCP notes that while its been known since 1922 that Vitamin D is vital for bone health, recent research reveals its importance in many other body functions, and suggests that the “sunshine” Vitamin is, for example,…
May 30, 2014 News by BioNews Staff MS Views & News Awards Questcor With “Recognition of Appreciation” Award Multiple Sclerosis Advocacy Questcor Pharmaceuticals, Inc. is a drug development company with a viable Multiple Sclerosis drug called H.P. ActharĀ® Gel, which is currently approved in the U.S. by the FDA for the treatment of acute exacerbations of multiple sclerosis in adults. However, in addition to developing and commercializing MS therapies, the…
May 29, 2014 News by admin Novartis And Tictrac Raise Awareness For MS With Health Tracking Challenge Pharmaceutical company Novartis and health tracking and analytics platform TictracĀ recently partnered up to supportĀ World Multiple Sclerosis Day and raise awareness for this disease by launching the campaign The 7-Day Challenge to Live Like You. The challenge, one of the first integrations of emerging technological trends by a pharmaceutical…
May 28, 2014 News by Charles Moore Study Finds MS Drug Gilenya May Point To Development Of New PTSD Therapy A new study on mice published in Nature Neuroscience finds that fingolimod (Novartis brand name Gilenya) a first-in-class sphingosine-1-phosphate-receptor modulator currently used in treating persons with severe relapsing remitting MS, may also have therapeutic value in treating Post Traumatic Stress Disorder (PTSD). The Nature Neuroscience study is titled…
May 27, 2014 News by Maureen Newman Acorda Therapeutics’ Online Multiple Sclerosis Resources To Be Demonstrated in Dallas At the 2014 Cooperative Meeting of the Consortium of Multiple Sclerosis Centers and the Americas Committee for Treatment and Research in Multiple Sclerosis on May 28-31 in Dallas, Acorda Therapeutics will be demonstrating its award-winning MS self⢠mobile app designed for patients with multiple sclerosis.
May 27, 2014 News by admin Committee for Medicinal Products for Human Use Adopts Positive Opinion For Plegridy As a Treatment for MS In The European Union TheĀ CommitteeĀ for Medicinal Products for Human UseĀ (CHMP) of the European Medicines AgencyĀ recently offered a positive opinion for the marketing authorization of Biogen Idec’s Plegridy therapy, a pegylated interferon administered subcutaneously for adults with relapsing-remitting multiple sclerosis (RRMS). The positive opinion will now be sent to the European Commission, which grants…
May 26, 2014 by Patricia Silva, PhD Multiple Sclerosis Drug NerventraĀ® (Laquinimod) Disapproved in EU; Drug Developers Will Continue Research Two pharmaceutical companies,Ā Teva Pharmaceutical Industries Ltd. (TEVA) and Active Biotech, have just confirmed reports that theĀ Committee for Medicinal Products for Human Use (CHMP) is not recommendingĀ NERVENTRA (laquinimod) for use in treatingĀ relapsing-remitting multiple sclerosis (RRMS) within the European Union (EU), according to a recent press release. Despite CHMP’s disapproval of…
May 26, 2014 by Patricia Silva, PhD Newly Acquired Patents For Multiple Sclerosis, Alzheimer’s DNA Therapies Spurs New Clinical Trials At Inovio Inovio Pharmaceuticals, a drug development company working on treatments that modulate therapeutically important immune responses with the help of T-cells, recently acquired the worldwide rights (apart from China), to conduct pre-clinical studies to produce products for possible therapies to treat and manage Alzheimer’s Disease (AD) and Multiple Sclerosis (MS).
May 23, 2014 by Charles Moore MRI Spectroscopy May Improve Accuracy in Predicting MS Progression A new study published this week in the Journal of the American Medical Association Neurology says that predicting disease evolution is becoming essential for optimizing treatment decision-making in multiple sclerosis (MS), in which pathologic damage typically includes demyelination, neuro-axonal loss, and astrogliosis. The study, entitled “Magnetic Resonance Spectroscopy…
May 22, 2014 News by Maureen Newman Orphan Drug Designation Granted to Treatment for Rare Multiple Sclerosis Drug Complication The Food and Drug Administration granted Orphan Drug Designation to Inhibikase Therapeutics’, Inc.Ā lead product, IkT-001Pro (imatinib), to treat progressive multifocal leukoencephalopathy (PML). According to the National Institute of Neurological Disorders and Stroke, PML affects the white matter of the brain usually through a…
May 22, 2014 by Charles Moore Hematopoietic Stem Cell Transplantation: MS Breakthrough Treatment Or Another “Liberation Therapy” Disappointment Shaping Up? Multiple Sclerosis (MS) is a devastating disease for many who become afflicted with the disease’s progressive form, often in the prime of their lives, with no cure and when the effectiveness of established MS treatment is so often disappointing. Discouragement can lead to pinning premature hope on unproven therapies…
May 20, 2014 by Patricia Silva, PhD Combination Therapy For Multiple Sclerosis Offers Promising Results In Recent Study Positive study results from a preliminary phase II clinical trialĀ for a new potential therapeutic intervention for the treatment of patients with relapsing remitting multiple sclerosis (RRMS) were recentlyĀ released at the American Academy of Neurology’s Annual Meeting in Philadelphia by Dr.Ā Rhonda Voskuhl, M.D., from the University of California, Los Angeles.
May 20, 2014 by Patricia Silva, PhD Researchers Explore Role of NAD In Cognitive Decline of Multiple Sclerosis Patients A group of researchers led byĀ Shin-ichiro Imai, MD, PhD, and Liana Roberts Stein, PhD,Ā fromĀ Washington University School of MedicineĀ in St. Louis have been working on pathways to trace cognitive decline in patients with multiple sclerosis (MS). It has been noted in previous research that brain cells derive energy for maintaining…
May 19, 2014 by Patricia Silva, PhD Clinical Professor Holds Lecture On Using Paleo Diet To Control MS According to a recent article by Beth Roessner at the Desert Sun,Ā some Multiple Sclerosis patients are beginning to utilize healthier diets and eating habits to complement conventional treatments for their disease — an approach that even some researchers are beginning to study. Erin Davis, a 40 year-old woman,…
May 16, 2014 by Charles Moore Researchers Report Encouraging Results in Mouse Model MS Stem Cell Therapy Research Scientists at the Scripps Research Institute (TSRI), the University of California (UC), Irvine and The University of Utah report that mice crippled by an autoimmune disease similar to multiple sclerosis (MS) regained the ability to walk and run after a team of researchers implanted human stem cells…
May 16, 2014 by Patricia Silva, PhD New Secondary Progressive MS Drug Trial Completes Enrollment Opexa Therapeutics, Inc., a drug delivery company based in The Woodlands, Texas, has been making significant progress in researching and developing TcelnaĀ®,Ā aĀ breakthrough T-cell immunotherapyĀ for multiple sclerosis (MS). The company recently announced they have reached their enrollment mark for conducting a Phase IIb clinical trial to testĀ Tcelna as a viable…